Loading...

Esperion Therapeutics, Inc.

ESPR•NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$0.91
$0.04(5.19%)

Esperion Therapeutics, Inc. (ESPR) Stock Overview

Explore Esperion Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
185.66%
↑ 185.66%
Profit Growth
$-0.78
↑ 75.27%
EPS Growth
$-0.78
↑ 86.21%
Operating Margin
-15.40%
↑ 134.97%
ROE
40.07%
↑ 75.27%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$8.00
Average$8.00
High$8.00

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

CEO

Mr. Sheldon L. Koenig

Employees

304

Headquarters

3891 Ranchero Drive, Ann Arbor, MI

Founded

2013

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.